Human Insulin Market Analysis 2026

Market Dynamics of the Human Insulin Market

Key Drivers of the Human Insulin Market

• Increasing the prevalence of diabetes can help the market to grow.

Diabetes is a chronic metabolic condition characterized by elevated blood sugar levels caused by the body's ineffective or inadequate use of insulin. The prevalence of diabetes is rising globally due to a multitude of factors, including sedentary lives, poor eating habits, changing lifestyles, and increased rates of obesity. According to estimates for the future, the number of persons with diabetes is expected to continue rising, as per the World Health Organisation (WHO). 
Human insulin is a vital medication used to treat diabetes because it helps regulate blood sugar levels and prevent complications from the disease. As the number of people with diabetes rises, so does the need for human insulin products, such as injectable insulin formulations including rapid-acting, short-acting, intermediate-acting, and long-acting insulin. Diabetes is getting more and more frequent, which increases the demand for human insulin goods on the market and drives innovation, R&D, and development in the human insulin market to serve the expanding therapeutic demands of diabetic patients. Hence increasing the prevalence of diabetes can help the market to grow. 
•    For instance, according to NCBI there are currently 246 million diabetics (46 percent of the population in the 40–59 age range), and by 2025, that number is expected to rise to 380 million.

(Source:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068646/#:~:text=According%20to%20an%20estimate%20of,to%20380%20m%20by%202025).

• Technological development helps the market to grow.

the advancements in diabetes control technologies and treatment approaches. With the advent of cutting-edge glucose monitors, innovative insulin administration techniques, and digital health solutions, patient outcomes and quality of life have significantly improved as a result of technological advancements in diabetes care. Thanks to advancements in insulin delivery technology such as insulin pens, insulin pumps, continuous glucose meters (CGMs), and closed-loop insulin delivery systems, patients with diabetes now have greater alternatives, convenience, and precision when it comes to insulin administration. This state-of-the-art technology allows for better glycemic control, a decreased risk of hypo- and hyperglycemia, and improved overall management of diabetes
The integration of electronic medical platforms, mobile applications, and data analytics tools allows patients and healthcare providers to monitor blood sugar levels, adjust treatment plans in real time, and track insulin dosages, all of which contribute to personalized and proactive diabetes care. Thanks to developments in diabetes treatment technology, it is now possible to create novel human insulin formulations and delivery systems that are customized to meet the changing needs of people with the condition. This leads to increased competitiveness and commercial expansion in the human insulin industry. Hence, technological development helps the market to grow 
•    For instance, according to the report by NLM, Scientists discovered a technique called Recombinant DNA that allowed them to introduce a human gene into the genetic makeup of a common bacterium. 
The human gene's encoded protein could now be produced by this "recombinant" microorganism.

(Source:https://www.nlm.nih.gov/exhibition/fromdnatobeer/exhibition-interactive/recombinant-DNA/recombinant-dna-technology-alternative.html).

Restraint of the Human Insulin Market

• The higher price of insulin hampers the market.

Costs associated with prescription insulin have sparked discussion and concern, particularly in areas where individuals are mostly responsible for covering their medical expenses. Although diabetes can save a person's life, many diabetics are finding the disease expensive due to its fast-rising costs, especially those without access to subsidized healthcare or proper insurance. Increased insulin expenses may make it more difficult to control diabetes by making patients and their families face financial difficulty, medication non-adherence, and drug restrictions. Moreover, they may raise the chance of developing diabetes-related problems. Coordinated efforts to promote price transparency, foster competition among producers, and expand the supply of readily available insulin formulations are necessary to lower costs and enhance patient access to vital diabetic care. The higher price of insulin hampers the market 
•    For instance, according to the article by Lilly Investors, Eli Lilly & Company announced an extension of its Insulin Value Programme, which caps patient out-of-pocket expenses at $35 or less per month, and price reductions of 70% for its most frequently given insulins. Lilly is taking these steps to help Americans who might struggle to navigate a complicated healthcare system that might prevent them from accessing inexpensive insulin and to make Lilly's insulin easier to get.

Impact of the COVID-19 on the Human Insulin Market

The fewer people are choosing to treat their diabetes as a result of the COVID-19 pandemic, the demand for insulin has been hindered. Furthermore, major industry participants experienced a considerable reduction in their earnings as a result of the COVID-19 epidemic. Insulin sales were impacted, particularly in the first half of 2020, by the decrease in the number of diabetes tests performed and the decreased attention paid to disease management beyond COVID-19 and other significant indicators.  This is about the impact of the pandemic. 

Opportunities of the Human Insulin Market

• Increasing demand for bio-similar insulin can create new opportunities.

The market's need for insulin is greatly increased by the rise in the production of biosimilar insulin. Diabetes care is now more accessible and economical because of the availability of biosimilar insulins, which are more reasonably priced than their branded equivalents. Biosimilars address economic concerns related to diabetes therapy while preserving quality and efficacy, which are concerns shared by patients and healthcare systems. Patient adoption is fueled by this cost-effectiveness, which promotes market expansion. Additionally, the manufacturing of biosimilars broadens the number of insulin options available to patients and healthcare professionals, which in turn grows the insulin market.
The insulin market is changing as a result of the incorporation of telemedicine into diabetes management. By facilitating remote consultations and monitoring, telemedicine improves patient care. It encourages patients to follow their insulin regimes and offers them real-time support. By using telehealth solutions, the industry reaches underserved areas and improves 
the accessibility and convenience of diabetes management. 
To improve patient outcomes, telemedicine supports insulin treatment by providing patient education, data-driven diabetes management, and routine follow-ups. In addition to enhancing patient care, this integration increases market demand by addressing the changing requirements of healthcare professionals and patients in the ever-changing healthcare environment. Increasing demand for bio-similar insulin can create new opportunities.

Recent Development

•    On 26 April 2022, The Ministry of Health Malaysia awarded Biocon a three-year, $90 million contract to manufacture recombinant human insulin, called Insugen. The agreement strengthens Biocon's position and dedication to developing markets such as Malaysia.

•    On 29 November 2022, By working together to purchase Viatris Inc.'s biosimilar business, Biocon was able to improve its manufacturing research and development capacities. This calculated action sets them up for successful biosimilar market commercialization.

Based on the Human Insulin Market study mentioned above, it can be inferred that the global market for embedded hypervisors is anticipated to grow rapidly shortly. The market dynamics, segmentations, status and trends, and major players can all be understood and inferred from the research. It offers information on a range of subjects, including market size, current trends, the competitive environment, and the likelihood of future growth. This makes it possible for the reader to comprehend and obtain trustworthy market and industry data.

Frequently Asked Questions